AtriCure, Inc.

NASDAQ:ATRC

Medical - Instruments & Supplies

Healthcare
$55.45 +3.52%

+$0.96 today

Market cap
$2.82B
Beta
1.26
P/E (TTM)
-295.5
EPS (TTM)
-$0.10
52W Low $25.36High $43.18

Volume 0.60M

Average 0.77M

ATRC Interest Expense

Cost of servicing the company's debt during the period.

AtriCure, Inc.NASDAQ: ATRC

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense dips below year-ago levels

Q2 FY2026 interest expense of $1.32M fell 11.5% year over year, behind the +17.3% change in trailing-twelve-month interest expense. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.

Context

  • Interest expense amounted to 1.1% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -11.5% toward the trailing-twelve-month pace of +17.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.32M-1.6% QoQ
Last fiscal yearDec 2025
$5.88M-8.3% YoY
LTMJun 2026
$7.07M+17.3% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-11.5%——
1 year-8.3%——
3-year CAGR+5.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
5.88M USD
Year-over-year change
-8.3%
4-year CAGR
+4.6%

Interest Expense vs competitors

How ATRC compares with its peers on the latest reported figures

  • ATRC's LTM Jun 2026 interest expense of $7.07M is the 4th highest of the 5 companies compared; the peer median is $203.14M.
  • Its year-over-year change of +17.3% is the highest of 4, against a peer median of -9.0%.
  • Interest expense amounts to 1.2% of revenue for ATRC, versus a peer median of 1.8%.
ATRC Competitors Peer median
Interest Expense for ATRC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDTMedtronic plcLTM Jul 2026$725M -1.8%+4.0%1.9%
BSXBoston Scientific CorporationLTM Jun 2026$363M -9.0%-9.1%1.7%
LIVNLivaNova PLCLTM Sep 2026$43.28M -20.1%+0.7%2.9%
ATRCAtriCure, Inc.LTM Jun 2026$7.07M +17.3%+5.6%1.2%
EWEdwards Lifesciences CorporationLTM Jun 2026$0 ——0.0%
Peer median (excluding ATRC) $203.14M-9.0%+0.7%1.8%

Competitors are the stored peer set for ATRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue274.33M330.38M399.25M465.31M534.53M
Cost of Revenue68.47M84.44M98.88M117.78M136.79M
Gross Profit205.86M245.94M300.37M347.52M397.74M
Gross Margin75.0%74.4%75.2%74.7%74.4%
Research & Development48.51M57.34M73.92M96.18M90.17M
Selling, General & Admin204.65M231.27M253.14M291.36M311.02M
Operating Expenses150.66M288.61M327.05M387.54M401.19M
Depreciation & Amortization10.44M11.71M14.81M18.73M20.53M
EBITDA65.75M(29.5M)(8.11M)(18.53M)16.25M
EBITDA Margin24.0%-8.9%-2.0%-4.0%3.0%
Operating Income55.21M(42.67M)(26.68M)(40.01M)(3.45M)
Operating Margin20.1%-12.9%-6.7%-8.6%-0.6%
Interest Income466K1.99M3.79M4.43M4.48M
Interest Expense4.92M4.99M6.93M6.41M5.88M
Other Income / Expenses(4.82M)(3.53M)(3.16M)(3.66M)(6.72M)
Income Before Tax50.39M(46.2M)(29.85M)(43.67M)(10.16M)
Pre-Tax Margin18.4%-14.0%-7.5%-9.4%-1.9%
Income Tax Expense188K268K591K1.02M1.29M
Net Income50.2M(46.47M)(30.44M)(44.7M)(11.45M)
Net Margin18.3%-14.1%-7.6%-9.6%-2.1%
EPS (Basic)1.11(1.02)(0.66)(0.95)(0.24)
EPS (Diluted)1.09(1.02)(0.66)(0.95)(0.24)
Weighted Avg Shares45.07M45.74M46.31M46.97M47.75M
Weighted Avg Shares (Diluted)46.04M45.74M46.31M46.97M47.75M

AtriCure, Inc.

NASDAQ:ATRC

Intrinsic Alpha fair value

Locked

Current Price

$55.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.